Attenuated and replication-competent vaccinia virus strains M65 and M101 with distinct biology and immunogenicity as potential vaccine candidates against pathogens

Journal of Virology

Volumn 87, Issue 12, 2013, Pages 6955-6974

  Sánchez Sampedro, Lucas ^a   Gómez, Carmen Elena ^a   Mejías Pérez, Ernesto ^a   Pérez Jiménez, Eva ^a,b   Oliveros, Juan Carlos ^a   Esteban, Mariano ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^b CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

LEISHMANIA VACCINE; RECEPTOR FOR ACTIVATED C KINASE; UNCLASSIFIED DRUG; VACCINIA VACCINE; VIRUS ANTIGEN; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; EMBRYO; ERYTHROLEUKEMIA CELL; FEMALE; GENE DELETION; GENOME ANALYSIS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION PREVENTION; LEISHMANIA INFANTUM; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; OPEN READING FRAME; PHENOTYPIC VARIATION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SKIN LEISHMANIASIS; VACCINIA VIRUS; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS GENOME; VIRUS MORPHOGENESIS; VIRUS MUTANT; VIRUS REPLICATION; VIRUS STRAIN; VIRUS VIRULENCE;

ANIMALS; ANTIGENS, PROTOZOAN; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CHICK EMBRYO; FEMALE; FIBROBLASTS; GENETIC VECTORS; HELA CELLS; HUMANS; IMMUNIZATION; KIDNEY; LEISHMANIASIS, CUTANEOUS; MICE; MUTATION; PROTOZOAN PROTEINS; SERIAL PASSAGE; VACCINES; VACCINES, ATTENUATED; VACCINIA VIRUS; VIRUS REPLICATION;

LEISHMANIA INFANTUM; MUS; POXVIRIDAE; VACCINIA VIRUS;

EID: 84878533459     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03013-12     Document Type: Article

References (79)

1. Gómez CE, Najera JL, Krupa M, Perdiguero B, Esteban M. 2011. MVA and NYVAC as vaccines against emergent infectious diseases and cancer. Curr. Gene Ther. 11:189-217.
2. Gómez CE, Najera JL, Krupa M, Esteban M. 2008. The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr. Gene Ther. 8:97-120.
3. Esteban M. 2009. Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS. Hum. Vaccin. 5:867-871.
4. Pantaleo G, Esteban M, Jacobs B, Tartaglia J. 2010. Poxvirus vectorbased HIV vaccines. Curr. Opin. HIV AIDS 5:391-396.
5. Gómez CE, Perdiguero B, Garcia-Arriaza J, Esteban M. 2012. Poxvirus vectors as HIV/AIDS vaccines in humans. Hum. Vaccin. Immunother. 8:1192-1207.
6. Nájera JL, Gómez CE, García-Arriaza J, Sorzano CO, Esteban M. 2010. Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens. PLoS One 5:e11406. doi:10.1371/journal.pone.0011406.
7. Kibler KV, Gomez CE, Perdiguero B, Wong S, Huynh T, Holechek S, Arndt W, Jimenez V, Gonzalez-Sanz R, Denzler K, Haddad EK, Wagner R, Sekaly RP, Tartaglia J, Pantaleo G, Jacobs BL, Esteban M. 2011. Improved NYVAC-based vaccine vectors. PLoS One 6:e25674. doi:10 .1371/journal.pone.0025674.
8. Lai AC, Pogo BG. 1989. Characterization of vaccinia virus deletion mutants isolated from persistently infected Friend erythroleukemia cells. Virus Res. 12:239-250.
9. Pogo BG, Friend C. 1982. Persistent infection of Friend erythroleukemia cells with vaccinia virus. Proc. Natl. Acad. Sci. U. S. A. 79:4805-4809.
10. Paez E, Dallo S, Esteban M. 1987. Virus attenuation and identification of structural proteins of vaccinia virus that are selectively modified during virus persistence. J. Virol. 61:2642-2647.
11. Paez E, Dallo S, Esteban M. 1985. Generation of a dominant 8-MDa deletion at the left terminus of vaccinia virus DNA. Proc. Natl. Acad. Sci. U. S. A. 82:3365-3369.
12. McMahon-Pratt D, Rodriguez D, Rodriguez JR, Zhang Y, Manson K, Bergman C, Rivas L, Rodriguez JF, Lohman KL, Ruddle NH. 1993. Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection. Infect. Immun. 61:3351-3359.
13. Li S, Rodrigues M, Rodriguez D, Rodriguez JR, Esteban M, Palese P, Nussenzweig RS, Zavala F. 1993. Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8 T-cell-mediated protective immunity against malaria. Proc. Natl. Acad. Sci. U. S. A. 90:5214-5218.
14. Bloom DC, Edwards KM, Hager C, Moyer RW. 1991. Identification and characterization of two nonessential regions of the rabbitpox virus genome involved in virulence. J. Virol. 65:1530-1542.
15. Rodriguez JF, Rodriguez D, Rodriguez JR, McGowan EB, Esteban M. 1988. Expression of the firefly luciferase gene in vaccinia virus: a highly sensitive gene marker to follow virus dissemination in tissues of infected animals. Proc. Natl. Acad. Sci. U. S. A. 85:1667-1671.
16. World Health Organization. 2004. Report of the Scientific Working Group meeting on leishmaniasis. TDR Research Publications, Geneva, Switzerland.
17. Ahmed SBH, Bahloul C, Robbana C, Askri S, Dellagi K. 2004. A comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to L. major. Vaccine 22:1631-1639.
18. Eckert D, Williams O, Meseda CA, Merchlinsky M. 2005. Vaccinia virus nicking-joining enzyme is encoded by K4L (VACWR035). J. Virol. 79: 15084-15090.
19. Gershon PD. 2004. Studying vaccinia virus RNA processing in vitro. Methods Mol. Biol. 269:151-168.
20. Pérez-Jiménez E, Kochan G, Gherardi MM, Esteban M. 2006. MVALACK as a safe and efficient vector for vaccination against leishmaniasis. Microbes Infect. 8:810-822.
21. Gómez CE, Najera JL, Domingo-Gil E, Ochoa-Callejero L, Gonzalez-Aseguinolaza G, Esteban M. 2007. Virus distribution of the attenuated MVA and NYVAC poxvirus strains in mice. J. Gen. Virol. 88:2473-2478.
22. Didierlaurent A, Ramirez JC, Gherardi M, Zimmerli SC, Graf M, Orbea HA, Pantaleo G, Wagner R, Esteban M, Kraehenbuhl JP, Sirard JC. 2004. Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses. Vaccine 22:3395-3403.
23. Ramsay AJ, Leong KH, Ramshaw IA. 1997. DNA vaccination against virus infection and enhancement of antiviral immunity following consecutive immunization with DNA and viral vectors. Immunol. Cell Biol. 75: 382.
24. Chakrabarti S, Brechling K, Moss B. 1985. Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques. Mol. Cell. Biol. 5:3403-3409.
25. Li H, Durbin R. 2009. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25:1754-1760.
26. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R. 2009. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25:2078-2079.
27. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, DePristo MA. 2010. The Genome Analysis Toolkit: a MapReduce framework for analyzing nextgeneration DNA sequencing data. Genome Res. 20:1297-1303.
28. Mooij P, Balla-Jhagjhoorsingh SS, Koopman G, Beenhakker N, van Haaften P, Baak I, Nieuwenhuis IG, Kondova I, Wagner R, Wolf H, Gomez CE, Najera JL, Jimenez V, Esteban M, Heeney JL. 2008. Differential CD4versus CD8T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates. J. Virol. 82:2975-2988.
29. García-Arriaza J, Najera JL, Gomez CE, Sorzano CO, Esteban M. 2010. Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions. PLoS One 5:e12395. doi:10.1371/journal.pone.0012395.
30. Nájera JL, Gomez CE, Garcia-Arriaza J, Sorzano CO, Esteban M. 2010. Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens. PLoS One 5:e11406. doi:10.1371/journal.pone.0011406.
31. Ramírez JC, Gherardi MM, Esteban M. 2000. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B-and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J. Virol. 74:923-933.
32. Rodriguez D, Rodriguez JR, Rodriguez JF, Trauber D, Esteban M. 1989. Highly attenuated vaccinia virus mutants for the generation of safe recombinant viruses. Proc. Natl. Acad. Sci. U. S. A. 86:1287-1291.
33. García-Arriaza J, Najera JL, Gomez CE, Tewabe N, Sorzano CO, Calandra T, Roger T, Esteban M. 2011. A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses. PLoS One 6:e24244. doi:10.1371/journal.pone .0024244.
34. Unterholzner L, Sumner RP, Baran M, Ren H, Mansur DS, Bourke NM, Randow F, Smith GL, Bowie AG. 2011. Vaccinia virus protein C6 is a virulence factor that binds TBK-1 adaptor proteins and inhibits activation of IRF3 and IRF7. PLoS Pathog. 7:e1002247. doi:10.1371/journal.ppat .1002247.
35. Symons JA, Adams E, Tscharke DC, Reading PC, Waldmann H, Smith GL. 2002. The vaccinia virus C12L protein inhibits mouse IL-18 and promotes virus virulence in the murine intranasal model. J. Gen. Virol. 83: 2833-2844.
36. Gardner JD, Tscharke DC, Reading PC, Smith GL. 2001. Vaccinia virus semaphorin A39R is a 50-55 kDa secreted glycoprotein that affects the outcome of infection in a murine intradermal model. J. Gen. Virol. 82: 2083-2093.
37. Palacios S, Perez LH, Welsch S, Schleich S, Chmielarska K, Melchior F, Locker JK. 2005. Quantitative SUMO-1 modification of a vaccinia virus protein is required for its specific localization and prevents its selfassociation. Mol. Biol. Cell 16:2822-2835.
38. Wilcock D, Duncan SA, Traktman P, Zhang WH, Smith GL. 1999. The vaccinia virus A4OR gene product is a nonstructural, type II membrane glycoprotein that is expressed at the cell surface. J. Gen. Virol. 80(Pt 8): 2137-2148.
39. Chernos VI, Vovk TS, Ivanova ON, Antonova TP, Loparev VN. 1993. Insertion mutants of the vaccinia virus. The effect of inactivating E7R and D8L genes on the biological properties of the virus. Mol. Gen. Mikrobiol. Virusol. 1993:30-34. (In Russian.)
40. Hsiao JC, Chung CS, Chang W. 1999. Vaccinia virus envelope D8L protein binds to cell surface chondroitin sulfate and mediates the adsorption of intracellular mature virions to cells. J. Virol. 73:8750-8761.
41. Senkevich TG, Ojeda S, Townsley A, Nelson GE, Moss B. 2005. Poxvirus multiprotein entry-fusion complex. Proc. Natl. Acad. Sci. U. S. A. 102: 18572-18577.
42. Earley AK, Chan WM, Ward BM. 2008. The vaccinia virus B5 protein requires A34 for efficient intracellular trafficking from the endoplasmic reticulum to the site of wrapping and incorporation into progeny virions. J. Virol. 82:2161-2169.
43. Blasco R, Moss B. 1991. Extracellular vaccinia virus formation and cellto-cell virus transmission are prevented by deletion of the gene encoding the 37,000-Dalton outer envelope protein. J. Virol. 65:5910-5920.
44. Honeychurch KM, Yang G, Jordan R, Hruby DE. 2007. The vaccinia virus F13L YPPL motif is required for efficient release of extracellular enveloped virus. J. Virol. 81:7310-7315.
45. Roper RL, Moss B. 1999. Envelope formation is blocked by mutation of a sequence related to the HKD phospholipid metabolism motif in the vaccinia virus F13L protein. J. Virol. 73:1108-1117.
46. Domi A, Weisberg AS, Moss B. 2008. Vaccinia virus E2L null mutants exhibit a major reduction in extracellular virion formation and virus spread. J. Virol. 82:4215-4226.
47. Arakawa Y, Cordeiro JV, Schleich S, Newsome TP, Way M. 2007. The release of vaccinia virus from infected cells requires RhoA-mDia modulation of cortical actin. Cell Host Microbe 1:227-240.
48. González JM, Esteban M. 2010. A poxvirus Bcl-2-like gene family involved in regulation of host immune response: sequence similarity and evolutionary history. Virol. J. 7:59.
49. Cooray S, Bahar MW, Abrescia NG, McVey CE, Bartlett NW, Chen RA, Stuart DI, Grimes JM, Smith GL. 2007. Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic protein. J. Gen. Virol. 88(Pt 6):1656-1666.
50. DiPerna G, Stack J, Bowie AG, Boyd A, Kotwal G, Zhang Z, Arvikar S, Latz E, Fitzgerald KA, Marshall WL. 2004. Poxvirus protein N1L targets the I-kappaB kinase complex, inhibits signaling to NF-kappaB by the tumor necrosis factor superfamily of receptors, and inhibits NF-kappaB and IRF3 signaling by toll-like receptors. J. Biol. Chem. 279:36570-36578.
51. Zhu W, Fang Q, Zhuang K, Wang H, Yu W, Zhou J, Liu L, Tien P, Zhang L, Chen Z. 2007. The attenuation of vaccinia Tian Tan strain by the removal of the viral M1L-K2L genes. J. Virol. Methods 144:17-26.
52. Colamonici OR, Domanski P, Sweitzer SM, Larner A, Buller RM. 1995. Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling. J. Biol. Chem. 270: 15974-15978.
53. Moore JB, Smith GL. 1992. Steroid hormone synthesis by a vaccinia enzyme: a new type of virus virulence factor. EMBO J. 11:1973-1980.
54. Da Silva M, Shen L, Tcherepanov V, Watson C, Upton C. 2006. Predicted function of the vaccinia virus G5R protein. Bioinformatics 22: 2846-2850.
55. Da Silva M, Upton C. 2009. Vaccinia virus G8R protein: a structural ortholog of proliferating cell nuclear antigen (PCNA). PLoS One 4:e5479. doi:10.1371/journal.pone.0005479.
56. Bayliss CD, Smith GL. 1996. Vaccinia virion protein I8R has both DNA and RNA helicase activities: implications for vaccinia virus transcription. J. Virol. 70:794-800.
57. Resch W, Moss B. 2005. The conserved poxvirus L3 virion protein is required for transcription of vaccinia virus early genes. J. Virol. 79:14719-14729.
58. Mohamed MR, Niles EG. 2001. The viral RNA polymerase H4L subunit is required for Vaccinia virus early gene transcription termination. J. Biol. Chem. 276:20758-20765.
59. Kovacs GR, Moss B. 1996. The vaccinia virus H5R gene encodes late gene transcription factor 4: purification, cloning, and overexpression. J. Virol. 70:6796-6802.
60. Beaud G, Beaud R, Leader DP. 1995. Vaccinia virus gene H5R encodes a protein that is phosphorylated by the multisubstrate vaccinia virus B1R protein kinase. J. Virol. 69:1819-1826.
61. Launois P, Pingel S, Himmelrich H, Locksley R, Louis J. 2007. Different epitopes of the LACK protein are recognized by V beta 4 V alpha 8 CD4 T cells in H-2b and H-2d mice susceptible to Leishmania major. Microbes Infect. 9:1260-1266.
62. Perkus ME, Tartaglia J, Paoletti E. 1995. Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases. J. Leukoc. Biol. 58: 1-13.
63. Jacobs BL, Langland JO, Kibler KV, Denzler KL, White SD, Holechek SA, Wong S, Huynh T, Baskin CR. 2009. Vaccinia virus vaccines: past, present and future. Antiviral Res. 84:1-13.
64. Abaitua F, Rodriguez JR, Garzon A, Rodriguez D, Esteban M. 2006. Improving recombinantMVAimmune responses: potentiation of the immune responses to HIV-1 withMVAandDNAvectors expressing Env and the cytokines IL-12 and IFN-gamma. Virus Res. 116:11-20.
65. Dai K, Liu Y, Liu M, Xu J, Huang W, Huang X, Liu L, Wan Y, Hao Y, Shao Y. 2008. Pathogenicity and immunogenicity of recombinant Tiantan Vaccinia Virus with deleted C12L and A53R genes. Vaccine 26:5062-5071.
66. Karkhanis LU, Ross TM. 2007. Mucosal vaccine vectors: replicationcompetent versus replication-deficient poxviruses. Curr. Pharm. Des. 13: 2015-2023.
67. Weyer J, Rupprecht CE, Mans J, Viljoen GJ, Nel LH. 2007. Generation and evaluation of a recombinant modified vaccinia virus Ankara vaccine for rabies. Vaccine 25:4213-4222.
68. Kotwal GJ, Moss B. 1988. Analysis of a large cluster of nonessential genes deleted from a vaccinia virus terminal transposition mutant. Virology 167:524-537.
69. Tagaya I, Kitamura T, Sano Y. 1961. A new mutant of dermovaccinia virus. Nature 192:381-382.
70. Meyer H, Sutter G, Mayr A. 1991. Mapping of deletions in the genome ofthe highly attenuated vaccinia virusMVAand their influence on virulence. J. Gen. Virol. 72(Pt 5):1031-1038.
71. García MA, Gil J, Ventoso I, Guerra S, Domingo E, Rivas C, Esteban M. 2006. Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action. Microbiol. Mol. Biol. Rev. 70:1032-1060.
72. Elde NC, Child SJ, Eickbush MT, Kitzman JO, Rogers KS, Shendure J, Geballe AP, Malik HS. 2012. Poxviruses deploy genomic accordions to adapt rapidly against host antiviral defenses. Cell 150:831-841.
73. Seder RA, Darrah PA, Roederer M. 2008. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 8:247-258.
74. Reyes-Sandoval A, Wyllie DH, Bauza K, Milicic A, Forbes EK, Rollier CS, Hill AV. 2011. CD8 T effector memory cells protect against liverstage malaria. J. Immunol. 187:1347-1357.
75. Rigato PO, de Alencar BC, de Vasconcelos JR, Dominguez MR, Araujo AF, Machado AV, Gazzinelli RT, Bruna-Romero O, Rodrigues MM. 2011. Heterologous plasmidDNAprime-recombinant human adenovirus 5 boost vaccination generates a stable pool of protective long-lived CD8(+) T effector memory cells specific for a human parasite, Trypanosoma cruzi. Infect. Immun. 79:2120-2130.
76. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, Hoff ST, Andersen P, Reed SG, Morris SL, Roederer M, Seder RA. 2007. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 13:843-850.
77. Macedo AB, Sanchez-Arcila JC, Schubach AO, Mendonca SC, Marins-Dos-Santos A, de Fatima Madeira M, Gagini T, Pimentel MI, De Luca PM. 2012. Multifunctional CD4 T cells in patients with American cutaneous leishmaniasis. Clin. Exp. Immunol. 167:505-513.
78. Obst R, van Santen HM, Mathis D, Benoist C. 2005. Antigen persistence is required throughout the expansion phase of a CD4(+) T cell response. J. Exp. Med. 201:1555-1565.
79. Thorne SH. 2008. Oncolytic vaccinia virus: from bedside to benchtop and back. Curr. Opin. Mol. Ther. 10:387-392.